A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs CX 8998 (Primary)
- Indications Arrhythmias; Essential tremor
- Focus Proof of concept; Therapeutic Use
- Acronyms T-CALM Sudy
- Sponsors Cavion
- 20 Sep 2017 According to a Cavion media release, first patient has been enrolled in the study.
- 23 Jun 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 Status changed from planning to not yet recruiting.